APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight the tumor. APEIRON’s clinical lead program APN401 is a first-inclass autologous cellular therapy which enhances anti-tumor immunity by inhibiting the intracellular master checkpoint, Cbl-b. APEIRON’s projects and technologies are bolstered by a strong patent portfolio. APEIRON’s development expertise is validated through partnerships with leading pharmaceutical companies and academic institutions.
We are searching for an enthusiastic Clinical Study Manager
Provide mid-level operational oversight and leadership for a of US based early stage program in oncology
Professional & Personal Skills:
For the position we offer at least an annual gross salary of € 70.000, -. The actual remuneration package will be based on your professional experience, qualification and skills. Increased pay is possible.